Evidence map›Paper›PMID 28489488›Full record

ArticleRadiation research2017

Radiation-Induced Fibrosis: Mechanisms and Opportunities to Mitigate. Report of an NCI Workshop, September 19, 2016.

Deborah E Citrin, Pataje G S Prasanna, Amanda J Walker, Michael L Freeman, Iris Eke, Mary Helen Barcellos-Hoff, Molykutty J Arankalayil, Eric P Cohen, Ruth C Wilkins, Mansoor M Ahmed and 6 more

Registry-linked trialAbstract readConference Proceedings
In one paragraph

Article in Radiation research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01754909 (Mitigation of Radiation Pneumonitis and Fibrosis), which is not on this map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01754909 phase2completednot on this map

Mitigation of Radiation Pneumonitis and Fibrosis

TypeinterventionalSponsorVA Office of Research and DevelopmentRan2013 to 2018Enrolled50ConditionsLung Cancer, Radiation PneumonitisArmsEnalapril, placebo
3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 77 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Current Status of Research on Losartan in Tumour Therapy.Journal of cellular and molecular medicine · 2026
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. An Agent-Based Model of Radiation-Induced Lung Fibrosis.International journal of molecular sciences · 2022
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 11 institutions in 2 countries.

Deborah E Citrina   Radiation Oncology Branch, Center for Cancer Research, Bethesda, Maryland.
Pataje G S Prasannab   Radiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, Maryland.
Amanda J Walkerc   Office of Hematology and Oncology Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
Michael L Freemand   Department of Radiation Oncology, Vanderbilt School of Medicine, Nashville, Tennessee.
Iris Ekea   Radiation Oncology Branch, Center for Cancer Research, Bethesda, Maryland.
Mary Helen Barcellos-Hoffe   Department of Radiation Oncology, University of California, San Francisco, San Francisco, California.
Molykutty J Arankalayila   Radiation Oncology Branch, Center for Cancer Research, Bethesda, Maryland.
Eric P Cohenf   Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.
Ruth C Wilkinsg   Radiobiology Division, Consumer and Clinical Radiation Protection Bureau, Health Canada, Ottawa, Ontario.
Mansoor M Ahmedb   Radiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, Maryland.
Mitchell S Anscherh   Department of Radiation Oncology, Virginia Commonwealth University, Richmond, Virginia.
Benjamin Movsasi   Department of Radiation Oncology, Henry Ford Hospital, Detroit, Michigan.
Jeffrey C Buchsbaumb   Radiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, Maryland.
Marc S Mendoncah   Department of Radiation Oncology, Virginia Commonwealth University, Richmond, Virginia.
Thomas A Wynnk   National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
C Norman Colemanb   Radiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, Maryland.
Center for Cancer Research · USNational Cancer Institute · USVirginia Commonwealth University · USCenter for Drug Evaluation and Research · USHealth Canada · CAHenry Ford Hospital · USIndiana University – Purdue University Indianapolis · USNational Institute of Allergy and Infectious Diseases · USUniversity of California, San Francisco · USUniversity of Maryland, Baltimore · USVanderbilt University · US

Funding

Mechanisms of Normal Tissue Toxicity From IrradiationZIABC010850 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CITRIN, DEBORAH · 2009 to 2025
$19.4M
Mechanisms of Fibrosis in Asthma and Other Fibroproliferative DiseasesZIAAI001019 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI WYNN, THOMAS · 2009 to 2018
$7.1M
Nrf2 and Radiation-induced pulmonary fibrosis.R01HL112286 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI FREEMAN, MICHAEL L. · 2013 to 2016
$1.7M
Mitigation of Radiation Pneumonitis and FibrosisI01CX000569 · VA · CLEMENT J. ZABLOCKI VA MEDICAL CENTER · PI COHEN, ERIC PHIN · 2013 to 2017
–
CSRD VA I01 CX000569Intramural NIH HHS Z99 CA999999Intramural NIH HHS ZIA BC010850NCI NIH HHS HHSN261201200078CNHLBI NIH HHS R01 HL112286
6 · The paper itself

Abstract

A workshop entitled "Radiation-Induced Fibrosis: Mechanisms and Opportunities to Mitigate" (held in Rockville, MD, September 19, 2016) was organized by the Radiation Research Program and Radiation Oncology Branch of the Center for Cancer Research (CCR) of the National Cancer Institute (NCI), to identify critical research areas and directions that will advance the understanding of radiation-induced fibrosis (RIF) and accelerate the development of strategies to mitigate or treat it. Experts in radiation biology, radiation oncology and related fields met to identify and prioritize the key areas for future research and clinical translation. The consensus was that several known and newly identified targets can prevent or mitigate RIF in pre-clinical models. Further, basic and translational research and focused clinical trials are needed to identify optimal agents and strategies for therapeutic use. It was felt that optimally designed preclinical models are needed to better study biomarkers that predict for development of RIF, as well as to understand when effective therapies need to be initiated in relationship to manifestation of injury. Integrating appropriate endpoints and defining efficacy in clinical trials testing treatment of RIF were felt to be critical to demonstrating efficacy. The objective of this meeting report is to (a) highlight the significance of RIF in a global context, (b) summarize recent advances in our understanding of mechanisms of RIF,

Indexed as

Evidence-Based MedicineHumansNational Cancer Institute (U.S.)Pulmonary FibrosisRadiation PneumonitisRadiotherapyTreatment OutcomeUnited States

Identifiers

PMID28489488
PMCPMC5558616
OpenAlexW2612749342

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.